NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a post-effective amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The amendment relates to the registration of 3,000,000 ordinary shares and an equal number of warrants to purchase additional shares at a price of $1.50 per share. These securities were initially issued in private placements in June 2023 and April 2024, and the warrants are exercisable until June 2028 and April 2029, respectively. The registration also includes 70,964 ordinary shares issued to a placement agent as partial consideration for services related to the April 2024 offering. The registration allows the selling shareholders to offer these securities publicly, and the company will not receive any proceeds from the sales. NeuroSense's ordinary shares are listed on The Nasdaq Capital Market under the symbol 'NRSN'.

NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a post-effective amendment to its Form F-1 registration statement with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The amendment relates to the registration of 3,000,000 ordinary shares and an equal number of warrants to purchase additional shares at a price of $1.50 per share. These securities were initially issued in private placements in June 2023 and April 2024, and the warrants are exercisable until June 2028 and April 2029, respectively. The registration also includes 70,964 ordinary shares issued to a placement agent as partial consideration for services related to the April 2024 offering. The registration allows the selling shareholders to offer these securities publicly, and the company will not receive any proceeds from the sales. NeuroSense's ordinary shares are listed on The Nasdaq Capital Market under the symbol 'NRSN'.